In neonatal hypoxic-ischemic brain injury, a variety of potential early therapeutics have broadly been categorized into anti-oxidative, anti-inflammatory, anti-apoptotic, and anti-excitotoxic mechanisms, with melatonin and erythropoietin covering multiple mechanisms [231]. The gene discussed is EPO; the disease is brain injury.